UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K/A
(Amendment No.
1)
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of Report (Date of earliest event reported): July 9,
2020
SANARA MEDTECH INC.
(Exact
name of registrant as specified in its charter)
|
Texas
|
000-11808
|
59-2219994
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification No.)
|
|
1200
Summit Avenue, Suite 414
Fort
Worth, Texas
|
76102
|
|
(Address
of principal executive offices)
|
(zip
code)
|
Registrant’s
telephone number, including area code: (817)-529-2300
Securities
registered pursuant to Section 12(b) of the Act: None
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company
as defined in in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this
chapter).
Emerging growth company
☐
If an emerging growth company, indicate by
checkmark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the
Exchange Act. ☐
Explanatory
Note:
On July
14, 2020, Sanara MedTech Inc. (the “Company”) filed a
Current Report on Form 8-K, disclosing the voting results of the
shareholders at the Company’s Annual Meeting of Shareholders
held on July 9, 2020. This Amendment No. 1 to such Current Report
on Form 8-K discloses in accordance with Item 5.07 of Form 8-K the
Company’s decision as to the frequency which the Company will
submit an advisory vote of shareholders on the approval of
executive compensation.
Item
5.07 Submission of Matters to a Vote of Security
Holders
As
previously reported in such prior Current Report on Form 8-K, the
non-binding advisory vote of the Company’s shareholders on
the future frequency of advisory votes of shareholders on approval
of the Company’s executive compensation was:
73,503
votes for every year;
3,664
votes for every other year; and
4,941,639 votes for
every three years.
After
considering the foregoing results of the vote of shareholders, the
Company’s Board of Directors determined that the Company will
submit future advisory votes of shareholders on the approval of
executive compensation every three years until the next required
vote on the frequency of advisory shareholder votes on executive
compensation.
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Company
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
Sanara MedTech
Inc.
|
|
|
|
|
|
|
|
|
Date: October 14,
2020
|
By:
|
/s/ Michael D.
McNeil
|
|
|
|
|
Name: Michael D.
McNeil
|
|
|
|
|
Title: Chief
Financial Officer
|
|